Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype

The new CFTR modulator combination, elexacaftor/tezacaftor/ivacaftor (Trikafta) was approved by the FDA in October 2019 for treatment of Cystic Fibrosis in patients 6 years of age or older who have at least one F508del mutation in one allele and a minimal-function or another F508del mutation in the...

Full description

Saved in:
Bibliographic Details
Published in:Antibiotics (Basel)
Main Authors: Comegna, Marika, Terlizzi, Vito, Salvatore, Donatello, Colangelo, Carmela, Di Lullo, Antonella Miriam, Zollo, Immacolata, Taccetti, Giovanni, Castaldo, Giuseppe, Amato, Felice
Format: Artigo
Language:Inglês
Published: MDPI 2021
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8300667/
https://ncbi.nlm.nih.gov/pubmed/34356748
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/antibiotics10070828
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items